D r Streiner admits to possible harm to participants in placebo-controlled trials with his statement that they are a "necessary evil," even when effective drugs exist. His justification rests on his supposition that they produce "unambiguous" results, "fewer people are exposed to ADRs [adverse drug reactions]," and "the number of people receiving ineffective treatment is likely lower." He points to many flaws that occur in clinical trials that may adversely impact on the trial results: selection of inappropriate patients as subjects, problems with randomization, inadequate blinding, failure to give a therapeutic dosage of comparator drugs, incomplete follow-up, high drop-out rates, and incomplete or inaccurate reporting of trial results. While published trial results may inaccurately portray difference or no difference for one or several of these reasons, introducing a placebo control will not make up for these inadequacies. In fact, in some cases, it will exacerbate them.
As for the argument that placebo-controlled trials expose fewer people to risks, or to the possibility of receiving ineffective treatment, how does this make up for the failure to ask a clinically relevant question? One could have an even lower risk profile with no people exposed to trial risk by not doing the trial at all. The consequence would be the same: failure to provide clinically relevant results.
However, let us suppose for the moment that placebo controls can make up for these trial deficiencies. How does that justify exposing participants to potential harm by denying them access to effective therapy? On what moral or legal grounds do we expose one set of patients to risk for the benefit of other, future patients? This is an especially important question when the prospective patients are individuals who are seeking or already receiving care in the context of a therapeutic relationship. Psychiatric patients are frequently recruited into trials by their treating physicians in the context of making treatment decisions. This may be an extremely vulnerable situation for patients, in which one could well imagine them being disadvantaged. It may also involve the potential for a conflict of interest with those having a financial or professional interest in the trial.
Dr Streiner's arguments are interesting, but unconvincing, and conflict with recognized ethical and legal obligations. Physicians have a fiduciary relationship with their patients: the patient's interest must come first. They cannot waive their obligations toward those who participate in clinical trials for the benefit of others, even if the others include future patients.
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